The value of routine chronic graft-versus-host disease (GVHD) screening studies performed between 70 and 120 days after allogeneic marrow transplantation was retrospectively evaluated among 241 patients. All patients received methotrexate and cyclosporine for GVHD prophylaxis and survived without relapse more than 4 months after transplant. Ninety-one patients (38%) developed clinical extensive chronic GVHD requiring systemic therapy. Data on patients who developed clinical extensive chronic GVHD were compared with those on patients without chronic GVHD to determine which of the following screening tests predicted the subsequent development of clinical extensive chronic GVHD: skin biopsy, oral exam, lip biopsy, Schirmer's test, serum alkaline phosphatase, aspartate transaminase, immunoglobulin level and platelet count. In a univariable analysis, a positive oral examination and a low platelet count were predictive of chronic extensive GVHD development. In a multivariable analysis which adjusted for the contribution of other chronic GVHD risk factors, such as age and a history of acute GVHD none of the screening tests were predictive of chronic GVHD development. The risk factors in this multivariable analysis which had the strongest association with the development of chronic GVHD was a history of acute GVHD and use of corticosteroids at day 100 (RR = 3.9, P = 0.001). The use of corticosteroids for acute GVHD at day 100 had a predictive effect on chronic GVHD development independent of the grade of acute GVHD (RR = 2.1, P = 0.004). Based on these study results, the use of chronic GVHD screening tests may not be of value in predicting who will develop this complication. Patients on corticosteroids at day 100 should be considered for clinical trials to determine the efficacy of new immunosuppressive agents in preventing chronic GVHD.
Chronic graft-versus-host disease (GVHD) remains a major complication of allogeneic bone marrow transplantation and is the predominant contributor to late transplant-related mortality. Clinical characteristics include features similar to autoimmune diseases and the disease may involve various sites including skin, liver, mouth, eyes, intestines, esophagus, lungs and soft tissue. [1] [2] [3] The signs and symptoms have been extensively reviewed elsewhere. 4, 5 Immunosuppressive therapy can decrease morbidity and mortality, 6, 7 and, hence, predicting or detecting chronic GVHD before clinical deterioration is important. Patients at low risk for chronic GVHD may be candidates for early tapering of immunosuppression, whereas those at high risk for chronic GVHD may be candidates for more prolonged immunosuppression.
A previous report of chronic GVHD screening studies performed 70 to 120 days after transplant (day 100 screening tests) has shown that a positive skin biopsy, a preceding history of acute GVHD, and oral biopsies staining for IgA plasma cells were risk factors predicting the development of chronic GVHD. 8 It is noteworthy that that study, as well as others, were performed in recipients of HLA-identical sibling marrow given mainly the single agent methotrexate (MTX) for prevention of acute GVHD. [8] [9] [10] The current study, was undertaken to re-examine the predictive value of routine screening studies in 241 patients who were all given the more effective combination of MTX and cyclosporine (CsA) as GVHD prophylaxis.
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Materials and methods
Patients
Data were initially analyzed from 462 patients who received unmodified allogeneic marrow grafts in Seattle between 1 January 1991 and 31 December 1992 and who had survived longer than 75 days. Of these 462 patients, 146 were excluded for the following reasons: 24 died before day 120; 27 had cytogenetic or morphologic relapse of malignancy before day 120; 89 received agents other than MTX/CsA for GVHD prophylaxis; and six had screening studies for chronic GVHD performed after day 120. The population of interest for this analysis comprised 316 patients of whom 241 were considered at risk for the development of clinical extensive chronic GVHD after day 100 screening tests. The 75 remaining patients who had clinical extensive chronic GVHD at day 100 were included to show how often the screening tests were abnormal in these patients. Patients who developed only limited clinical or subclinical chronic GVHD were not treated with systemic immunosuppression unless they later developed clinical extensive disease. The criteria for grading chronic GVHD have been described elsewhere. 12 Follow-up for the occurrence of clinical extensive chronic GVHD among patients who were alive and without relapse was complete to 2 years for all but two patients who were both lost to follow-up about 18 months post-transplant.
Screening studies
Screening tests included skin biopsy, oral exam, lip biopsy, Schirmer's test of lacrimal gland function, serum alkaline phosphatase, aspartate transaminase, bilirubin, serum IgG levels and platelet counts. Other factors considered were histories of acute GVHD, corticosteroid treatment at day 100, patient age and degree of HLA disparity. The skin or lip biopsies were considered positive for GVHD if there were histologic changes consistent with lymphocytic infiltration of the epithelium with evidence of epithelial cell apoptosis.
1,2 Laboratory tests were considered positive if the bilirubin was Ͼ1.2 mg/dl; aspartate transaminase Ͼ50 IU; and for adults alkaline phosphatase Ͼ120 IU. For adults, IgG levels were considered decreased if Ͻ500 mg/dl. For children, the alkaline phosphatase and IgG levels were interpreted in relation to the child's age. 13 The Schirmer's test was abnormal if the average value of tear production in both eyes was Ͻ11 mm at 5 min. Platelet counts were considered decreased if Ͻ100 000/mm 3 .
Statistical methods
Univariable and multivariable Cox proportional hazards regression models were used.
14 Covariables were included in the multivariable models to adjust for the potential confounding effects of patient, donor and treatment characteristics associated with the risk of chronic GVHD. A forward stepwise approach was taken in constructing a base model containing the subset of the candidate prognostic factors, exclusive of the screening studies results, which made the greatest contribution to the model. Factors considered for inclusion in the base model were diagnosis and disease stage at the time of transplant, patient age, donor relationship and histocompatibility status, total body irradiation (TBI) dose, transplant year, patient/donor gender mismatch, history of acute GVHD, protocol-specified duration of cyclosporine prophylaxis, and if on corticosteroid therapy at the time of the screening tests. All patients except 24 received a standard 6 months of CsA prophylaxis unless they had or developed chronic GVHD. Those 24 patients were on arm two of a protocol comparing 6 months vs 24 months of CsA usage to prevent chronic GVHD. The protocol-specified duration of CsA prophylaxis takes into account the varying duration of CsA prophylaxis for some patients.
The contributions of the screening tests to the prediction of subsequent development of clinical extensive chronic GVHD were then evaluated in the context of this base model. Patients were considered to be at risk for chronic GVHD development if surviving more than 4 months after transplant without relapse, and thereafter until the time of hematologic relapse, death or last contact. A multivariable Cox proportional hazards regression model was then used to determine the specific contribution of each of the factors included in the base model. The duration of cyclosporine prophylaxis was modeled as a time-dependent covariate.
Results
Characteristics of all 316 patients are listed in Tables 1 and  2 . Twenty-four percent of patients (n = 75) had signs and symptoms of extensive clinical chronic GVHD at the time of testing and were included in Tables 1 and 2 to form a comparison group for the 241 patients analyzed in this study who did not have chronic GVHD at the time of testing. In Table 1 the numbers in parentheses represent the percentage of patients in the relevant treatment outcome group with the indicated characteristic. Forty-seven percent of patients (n = 150) did not develop subsequent chronic GVHD. Twenty-nine percent of patients (n = 91) later developed clinical extensive chronic GVHD at a median of 183 (range 97-884) days post-transplant. Three-quarters of the patients who developed chronic GVHD did so before day 230. Thirty percent of patients with grade 0, 37% of patients with grade I, 53% of patients with grade II, and 64% of patients with grade III acute GVHD developed chronic GVHD. Table 2 shows the results of nine individual screening studies tabulated by chronic GVHD outcome. Among the 241 patients at risk of developing chronic GVHD, a positive oral examination and a low platelet count were more frequently seen in those who developed chronic GVHD, than those who did not. Young children did not receive Schirmer's tests or lip biopsies. Table 3 shows the results of the univariable analysis for screening tests and patient characteristics. As expected from the results presented in Table 2 , in the univariable analysis, screening tests associated with clinical extensive chronic GVHD risk included thrombocytopenia at day 100 (RR = 1.9, P = 0.004) and a positive oral exam for GVHD (RR = 1.7, P = 0.02). Patient characteristics associated with chronic GVHD risk included steroid administration at day 100 (RR = 2.6, P Ͻ 0.001) and prior acute GVHD (RR = 2.5, P = 0.006). Prior acute GVHD even if analyzed as grades II-IV vs grades 0-I still conveyed a significant association with the development of clinical extensive chronic GVHD (data not shown). Other screening tests were not statistically significant predictors of the development of clinical extensive chronic GVHD in the univariable analysis. Table 4 presents the multivariable analysis of predictive factors. The multivariable model accounted for the effects of corticosteroid therapy at the time of screening, history of acute GVHD, donor relationship, histocompatibility, cyclosporine discontinuation and patient age (Table 4) . While the univariable analyses suggested that low platelet count and a positive oral examination were predictive of subsequent clinical extensive chronic GVHD, in the multi- variable analysis only a positive oral examination appeared to approach a suggestive association with subsequent chronic GVHD (RR = 1.5, likelihood ratio test P value (LRT-P) = 0.10). When accounting for the multiple hypotheses tests carried out in this analysis, this P value is not sufficiently small to be considered suggestive of an association. For patients who did not receive a Schirmer's test or lip biopsy even if all who developed chronic GVHD had positive tests and all who did not develop chronic GVHD had negative tests, the P values for those two screening tests were still not sufficiently statistically significant to suggest an association (data not shown). Table 5 provides relative risk estimates and LRT-P values corresponding to an evaluation of the other eight screening tests in the context of the multivariable model presented in Table 4 . There is no evidence that any of these eight screening tests provided an additional contribution to the prediction of chronic GVHD development. Although thrombocytopenia was associated with subsequent chronic GVHD in the univariable model, the predictive contribution Seventy-nine patients (53%) in group 1, 63 (84%) in group 2 and 61 (67%) in group 3 were receiving IV IgG. of thrombocytopenia disappeared when corticosteroid therapy was accounted for in the multivariable model. Among the 241 patients at risk for developing chronic GVHD, 118 had HLA-matched related donors and 123 had mismatched or unrelated donors. There was no evidence that screening tests were of value in predicting chronic GVHD incidence within the subgroup of patients with matched sibling donors or within the group of patients with unrelated or mismatched related donors (data not shown). Furthermore, the same strong association of chronic GVHD with corticosteroid usage was seen when the patient population was divided into those with HLA-matched related donors and those with mismatched or unrelated donors (data not shown). Figure 1 presents the cumulative incidence of chronic GVHD in three subgroups based on the presence or absence of acute GVHD and usage of corticosteroids. Of the 120 patients with a history of acute GVHD and still receiving corticosteroids at day 100, 50% developed chronic GVHD, whereas of the 72 patients with a history of acute GVHD but not on steroids at day 100, 29% developed GVHD, and of the 44 patients without a history of acute GVHD and not on steroids at day 100, only 16% developed GVHD.
While developing a multivariable analysis to determine the value of chronic GVHD screening studies, the observation was made that corticosteroid usage at day 100 conveys an additional risk factor for chronic GVHD development beyond that of a history of acute GVHD. This observation could be due to the corticosteroids themselves or the 'aggressiveness' of the acute GVHD. Two groups of patients with acute GVHD -those on corticosteroids at day 100 and those not on corticosteroids at day 100 -were examined to determine the major differences between them. Factors examined included overall grade of acute GVHD, 143  Table 4 Multivariable analysis of chronic GVHD development after screening tests (n = 241 patients) Table 4 , plus a covariate for the additional indicated factor. The likelihood ratio test (LRT) P values are for a test of the additional contribution of the corresponding factor to the model summarized in Table 4 .
which is a measure of the extent of GVHD (see Table 6 ). 15 Among all of the grades of acute GVHD, corticosteroid usage at day 100 was associated with chronic GVHD development although in some cases the sample size was too small to measure statistical significance. In addition, the grade of skin, liver and gut, acute GVHD; the time of onset of acute GVHD, the donor relationship, the TBI dose, the donor/patient gender and the patient age were examined (data not shown). As expected, the major difference was that those patients on corticosteroids at day 100 tended to have a higher overall acute GVHD score and more severe skin GVHD. (Those with severe acute GVHD of the liver or gut generally did not survive until day 100). This is consistent with previously published data which showed that acute GVHD is a powerful predictor of chronic GVHD. 16 Additionally, when stratified by acute GVHD grade, the day of onset of grades II-IV acute GVHD was a median of only 1 to 3 days later in the group of patients on corticosteroids at day 100.
Nevertheless, the association of corticosteroid usage with an increased risk of chronic GVHD was not fully accounted for by a higher overall GVHD grade nor a slightly later onset of acute GVHD. We examined the relationship between corticosteroid usage and chronic GVHD development in a multivariable model that was stratified on acute GVHD grade ( Table 7) . The model also accounted for Years after transplant Probability Figure 1 Cumulative incidence of subsequent chronic GVHD in patients free of GVHD at day 100 (n = 241 patients). -· -, Patients with a history of acute GVHD receiving corticosteroids at day 100 who developed chronic GVHD (n = 120); --, patients with a history of acute GVHD not receiving corticosteroids at day 100 (n = 72); ···, patients without a history of acute GVHD not receiving corticosteroids at day 100 (n = 44). The five patients who had no history of acute GVHD but were receiving corticosteroids at day 100 are not shown. ¼, Competing risk (relapse or death with chronic GVHD); -, censored (alive without relapse, second marrow transplant, or chronic GVHD).
Table 6
Acute GVHD grade, corticosteroid usage at day 100 and chronic GVHD development (n = 241 patients) patient age, degree of HLA mismatch and donor/patient relationship and day of onset of acute GVHD. In this model corticosteroid usage at day 100 still had an association with chronic GVHD development that was independent of acute GVHD grade (RR = 2.1, P = 0.004).
Acute
Discussion
The results of these analyses differ from those of preceding studies. 8, 9 Loughran et al 8 had previously evaluated screening tests. That study found that a positive skin biopsy, a prior history of acute GVHD, and oral biopsies with positive staining for IgA in plasma cells (not evaluated in this study) were risk factors in a multivariable analysis for the development of chronic GVHD. 8 In this study corticosteroid usage after day 50 was associated with an increased risk of clinical extensive chronic GVHD in a univariable analysis but not in a multivariable analysis.
One question which arises is why the screening tests, such as the skin biopsy, are no longer predictive in this series of patients. Firstly, this cohort differs from the previously published series because it included only patients given a combination of MTX and CsA for GVHD prophylaxis. Furthermore, this cohort included a large number of unrelated or mismatched marrow recipients (55%) who have more acute and chronic GVHD. 5 In the previous report, all patients received MTX alone for GVHD prophylaxis. 8 While the incidence of chronic GVHD has not changed with the combination of MTX and CsA (given to day 180) compared to MTX alone (given to day 102) evaluated in the previous study, it is unclear what impact the agents used for GVHD prophylaxis have on screening test results. 8, 17 Perhaps the cyclosporine alters the appearance of the dermal histologic findings and thus makes the skin biopsy more difficult to interpret.
Corticosteroids might also alter the histologic findings or 'mask' a positive test, thus, reducing the test's usefulness as a marker for chronic GVHD development. Moreover, 52% of the patients in the current study were receiving corticosteroids at the time of screening as compared to only 36% in the previous study. 8 We considered whether a skin biopsy might still be useful in patients not on corticosteroids at day 100. However, when the incidence of chronic GVHD was examined with respect to skin or lip biopsy results within corticosteroid treatment groups, there was no evidence to support this hypothesis ( Table 8 ). The absence of corticosteroid usage at day 100 did not increase the predictive value of the skin or lip biopsy in a statistically significant fashion. The reason that corticosteroid usage at day 100 increased the risk of chronic GVHD development is not fully explained by higher overall acute GVHD grade. One possibility is that corticosteroids could increase the number of infections as has been shown when methylprednisolone is used for GVHD prophylaxis. 18 In one study viral infections have been linked to chronic GVHD development. 19 Another possibility is that patients on corticosteroid therapy at day 100 had a form of acute GVHD that was more difficult to treat (as measured by the difficulty in tapering off the corticosteroids).
Whether there is a direct relationship between the use of corticosteroids and chronic GVHD cannot be determined from this study, as corticosteroids were used mainly to treat acute GVHD (a few patients received corticosteroids for other reasons such as asthma). Studies using corticosteroids as prophylaxis for acute GVHD are better able to address this question. In one study of acute GVHD prophylaxis by Deeg et al, 20 the combination of CsA and corticosteroids did not increase the risk of acute GVHD compared to CsA alone. 20 In another study by Storb et al, 21 patients with HLA-matched related donors given late prednisone (that is prednisone administered after the MTX course is completed) with MTX and CsA had an acute GVHD incidence of 25% vs 25% in those who received just MTX and CsA. Both these studies suggest that prednisone (at least when used after completion of a short course of MTX) does not predispose the patient to develop acute GVHD.
Corticosteroids might predispose patients to chronic GVHD development independent of other factors. One study using corticosteroids as acute GVHD prophylaxis reports chronic GVHD rates as low as 6%. 22 However, corticosteroid usage as therapy prior to transplant or for GVHD prophylaxis can be a risk factor for chronic GVHD development. 20, 21, 23 The results of two randomized prospective studies involving over 200 patients show that using corticosteroids for GVHD prophylaxis is associated with a higher risk of the development of clinical extensive chronic GVHD. 20, 21 How could corticosteroids potentially increase the risk of chronic GVHD? In rodents, thymocytes are sensitive to glucocorticoids and are killed in vitro while mature T cells derived from thymocytes are completely resistant to this apoptosis. 24 Perhaps the thymocytes that are killed by glucocorticoids are involved in the induction of tolerance. In other words, absence of thymic function might prevent the development of antigen-specific suppressor T cells thought to mediate tolerance and, thus, lead to chronic GVHD development. 25 This study suggests that patients can be stratified into three risk categories, eg low (not on corticosteroids, no history of acute GVHD), intermediate (not on corticosteroids but a history of acute GVHD), and high (those on corticosteroids at day 100). Furthermore, the study suggests that extensive screening tests do not appear to predict which patients will develop chronic GVHD.
Finally, these data point toward new approaches for the prevention of extensive clinical chronic GVHD. Since there were few new cases of chronic GVHD occurring more than 2 years after transplant consideration can be given as to whether 'continuous' immunosuppression (eg CsA for 2 years post-transplant) should be tested in prospective, controlled clinical trials in high risk groups, such as those on corticosteroids at day 100.
